Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-69086420 in Advanced Prostate Cancer
NCT04644770Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of JNJ-6420 in prostate cancer (PCa) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Adverse Events, Dose-Limiting Toxicity and 1 more. Started Nov 2020; status: active, not recruiting.
02
Drugs
JNJ-6420
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04644770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04644770.